As of November 6, 2026, Acrivon Therapeutics, Inc. is a publicly traded company (Nasdaq: ACRV). The largest holder reporting an active stake on Schedule 13D is RA Capital, at 28.8%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Kenneth Griffin (5.5%), Sands Capital Life Sciences Pulse Fund II, L.P. (5.3%) (Schedule 13D/A, April 23, 2026).
Is this your company?
About to sign with, pay or invest in Acrivon Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Acrivon Therapeutics, Inc. a real, registered company?
- Acrivon Therapeutics, Inc. files with the SEC under CIK 1781174 (its SEC filings).
- Its shares are listed under the ticker ACRV on Nasdaq (SEC company record).
- business address in Watertown, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Acrivon Therapeutics, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Sands Capital Life Sciences Pulse Fund II, L.P. (filed 2026-08-13).
Who are Acrivon Therapeutics, Inc.'s owners and officers?
Acrivon Therapeutics, Inc.: business address in Watertown, Massachusetts; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-08-13).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-13 | Sands Capital Life Sciences Pulse Fund Ii, L.P. | 5.3% |
| Schedule 13G/A, 2026-05-15 | Citadel Advisors LLC | 0% |
| Schedule 13D/A, 2026-04-23 | Ra Capital Management, L.P. | 28.8% |
| Schedule 13D/A, 2026-03-23 | Ra Capital Management, L.P. | 21.6% |
| Schedule 13G, 2025-11-21 | Kenneth Griffin | 5.5% |
| Schedule 13G/A, 2025-11-14 | Citadel Advisors LLC | 4.9% |
| Schedule 13G/A, 2025-08-13 | Sands Capital Life Sciences Pulse Fund Ii, L.P. | 6.8% |
Questions about who owns Acrivon Therapeutics, Inc.
Who owns Acrivon Therapeutics, Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Acrivon Therapeutics, Inc.: Ra Capital Management, L.P. (28.8%, Schedule 13D/A, filed 2026-04-23), Kenneth Griffin (5.5%, Schedule 13G, filed 2025-11-21) and Sands Capital Life Sciences Pulse Fund Ii, L.P. (5.3%, Schedule 13G/A, filed 2026-08-13).
Who are the largest shareholders of Acrivon Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Acrivon Therapeutics, Inc. on this page are Ra Capital Management, L.P. (28.8%), Kenneth Griffin (5.5%) and Sands Capital Life Sciences Pulse Fund Ii, L.P. (5.3%).
When did Ra Capital Management, L.P. buy into Acrivon Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Ra Capital Management, L.P. on this page is the Schedule 13D/A, filed 2026-03-23, reporting 21.6%; its latest, Schedule 13D/A filed 2026-04-23, reports 28.8%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 7 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Acrivon Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Acrivon Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Acrivon Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
10 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Acrivon Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a 10% owner: 3,104,139 shares (7.2% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-05-01).
- Perceptive Advisors, a 10% owner: 3,104,139 shares (7.2% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-05-01).
- Perceptive Life Sciences Master Fund Ltd., a 10% owner: 3,104,139 shares (7.2% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-05-01).
- , the executive vice president - business operations and a director: 2,615,911 shares (6.1% of shares outstanding), 2,230,052 held directly and 385,859 indirectly, on a joint filing (Form 4, 2026-08-27).
- , the chief executive and president: 2,615,911 shares (6.1% of shares outstanding), 2,230,052 held directly and 385,859 indirectly, on a joint filing (Form 4, 2026-08-27).
Shares outstanding: 42,853,362 as of 2026-08-07, from the company's latest SEC cover page.
How much has Acrivon Therapeutics, Inc. raised?
No fundraising or offering filing from Acrivon Therapeutics, Inc. is on file with us.
Keep reading
More on Acrivon Therapeutics, Inc. and the records around it.
Acrivon Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
Companies that share a holder
- Sands Capital Life Sciences Pulse Fund II, L.P. also filed stake reports on 3 other companies: Inhibikase Therapeutics, Inc. (Aug 2026), Alamar Biosciences, Inc. (Jul 2026), Beta Bionics, Inc. (Aug 2025)
- Citadel Advisors LLC also filed stake reports on 58 other companies: Quantinuum Inc. (Oct 2026), REALLOYS INC. (Oct 2026), STARFIGHTERS SPACE, INC. (Oct 2026)
- RA Capital Management, L.P. also filed stake reports on 100 other companies: Climb Bio, Inc. (Nov 2026), Bambusa Therapeutics, Inc. (Nov 2026), SOLID BIOSCIENCES INC. (Nov 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/acrivon-therapeutics